Skip to content
DataLookout
Menu

NCT06851767

Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy

StatusEnrolling by Invitation
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 69 versions: 40 with changes below, 10 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Interventions modified
  2. Notable Eligibility criteria shortened, about 18 words
    • Secondary endpoints: details revised at 1 of 5 entries
    • Study description expanded, about 13 words
  3. Notable Eligibility criteria expanded, about 112 wordsv65
  4. Minor Eligibility criteria revisedv56
  5. Study Status, Study Descriptionv55
Show 35 earlier versionsHide 35 earlier versions
  1. Minor Start date changed from estimate of May 21, 2025 to May 9, 2025v54
  2. Minor Start date: May 20, 2025 to May 21, 2025v53
  3. Minor Start date: May 19, 2025 to May 20, 2025v52
  4. Minor Start date: May 16, 2025 to May 19, 2025v51
  5. Minor Start date: May 15, 2025 to May 16, 2025v50
  6. Minor Start date: May 14, 2025 to May 15, 2025v49
  7. Minor Start date: May 13, 2025 to May 14, 2025v48
  8. Minor Start date: May 12, 2025 to May 13, 2025v47
  9. Minor Start date: May 11, 2025 to May 12, 2025v46
  10. Minor Start date: May 8, 2025 to May 11, 2025v45
  11. Minor Start date: May 7, 2025 to May 8, 2025v44
  12. Notable Trial status: Not Yet Recruiting to Enrolling by Invitation
    • Start date: May 6, 2025 to May 7, 2025
    v43
  13. Minor Start date: May 5, 2025 to May 6, 2025v42
  14. Minor Start date: May 4, 2025 to May 5, 2025v41
  15. Minor Start date: May 1, 2025 to May 4, 2025v40
  16. Minor Start date: Apr 30, 2025 to May 1, 2025v39
  17. Minor Start date: Apr 29, 2025 to Apr 30, 2025v38
  18. Minor Start date: Apr 28, 2025 to Apr 29, 2025v37
  19. Minor Start date: Apr 27, 2025 to Apr 28, 2025v36
  20. Minor Start date: Apr 24, 2025 to Apr 27, 2025v35
  21. Minor Start date: Apr 23, 2025 to Apr 24, 2025v34
  22. Minor Start date: Apr 22, 2025 to Apr 23, 2025v33
  23. Minor Start date: Apr 21, 2025 to Apr 22, 2025v32
  24. Minor Start date: Apr 20, 2025 to Apr 21, 2025v31
  25. Notable Primary and study completion dates: Dec 31, 2032 to Dec 31, 2034
    • Start date: Apr 16, 2025 to Apr 20, 2025
    v30
  26. Minor Start date: Apr 15, 2025 to Apr 16, 2025v29
  27. Minor Start date: Apr 13, 2025 to Apr 15, 2025v28
  28. Minor Start date: Apr 10, 2025 to Apr 13, 2025v27
  29. Minor Start date: Apr 9, 2025 to Apr 10, 2025v26
  30. Minor Start date: Apr 8, 2025 to Apr 9, 2025v25
  31. Minor Start date: Apr 7, 2025 to Apr 8, 2025v24
  32. Minor Start date: Apr 4, 2025 to Apr 7, 2025v23
  33. Minor Start date: Apr 3, 2025 to Apr 4, 2025v22
  34. Minor Start date: Apr 1, 2025 to Apr 3, 2025v21
  35. Minor Start date: Mar 31, 2025 to Apr 1, 2025v20
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Quantify frequency and severity of adverse events (AEs) related to study agent from infusion to 12 months after infusion.
Timeframe: 12 months

Secondary (5)

Evaluate percentage of participants with >= 5% mutation-repaired alleles in PBMCs.
Evaluate editing efficiency in peripheral blood cells (such as T, B, and natural killer [NK] cells).
Evaluate Immune reconstitution: a. T, B, and NK cell number improvement from baseline. b. Emergence of naive T cells and CD31+ recent thymic emigrants.c. B-cell function: immunoglobulin (Ig) production. d. Specific responses to vacci...
Evaluate clinical efficacy by improvement from baseline problems such as recurrent infection, chronic norovirus, protein-losing enteropathy, gastrointestinal complaints, growth failure, malnutrition, or immune dysregulation.
Evaluate frequency and severity of all study agent-related AEs and serious adverse events (SAEs) from time of study product infusion.

Arms and interventions

Single Arm StudyExperimental

Biologicals: Base-edited hematopoietic stem and progenitor cells

Drugs: Busulfan, Palifermin, Filgrastim, Plerixafor, Campath

Sites

1 site in 1 country

  • National Institutes of Health Clinical CenterBethesda, Maryland, United States